Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.

Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681.

PMID:
19188134
2.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5.

PMID:
21594665
3.

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G.

Br J Cancer. 2012 Apr 10;106(8):1367-73. doi: 10.1038/bjc.2012.85.

4.

Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Fabi A, Metro G, Di Benedetto A, Nisticò C, Vici P, Melucci E, Antoniani B, Perracchio L, Sperduti I, Milella M, Cognetti F, Mottolese M.

Oncology. 2010;78(2):141-9. doi: 10.1159/000312656.

PMID:
20389136
5.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group..

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

6.

Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.

Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G.

Asian Pac J Cancer Prev. 2015;16(7):2645-51.

7.

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Grell P, Fabian P, Khoylou M, Radova L, Slaby O, Hrstka R, Vyzula R, Hajduch M, Svoboda M.

Int J Oncol. 2012 Oct;41(4):1204-12. doi: 10.3892/ijo.2012.1576.

8.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885.

9.

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.

J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796.

PMID:
19398573
10.

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.

Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, Fujiwara Y.

Med Oncol. 2009;26(3):344-9. doi: 10.1007/s12032-008-9127-2.

PMID:
19016009
11.

PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.

Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S.

J BUON. 2013 Jan-Mar;18(1):44-50.

PMID:
23613387
13.

p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.

Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G.

Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2.

PMID:
25098276
14.

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X.

BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.

15.

Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.

Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE.

Clin Breast Cancer. 2005 Aug;6(3):247-52.

PMID:
16137436
16.

Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.

Adamczyk A, Niemiec J, Janecka A, Harazin-Lechowska A, Ambicka A, Grela-Wojewoda A, Domagała-Haduch M, Cedrych I, Majchrzyk K, Kruczak A, Ryś J, Jakubowicz J.

Pol J Pathol. 2015 Jun;66(2):133-41.

17.

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

Nishimura R, Okumura Y, Arima N.

Breast Cancer. 2008;15(1):57-64. doi: 10.1007/s12282-007-0014-z.

PMID:
18224396
18.

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.

Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.

Anticancer Res. 2006 Jan-Feb;26(1B):647-53.

19.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

20.

Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM.

Ann Oncol. 2008 Jul;19(7):1242-8. doi: 10.1093/annonc/mdn036.

PMID:
18334512

Supplemental Content

Support Center